# A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

> **NCT05040906** · PHASE3 · UNKNOWN · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 416 (estimated)

## Conditions studied

- Recruiting

## Interventions

- **DRUG:** H02+CHOP
- **DRUG:** Rituxan +CHOP

## Key facts

- **NCT ID:** NCT05040906
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-13
- **Primary completion:** 2023-10-13
- **Final completion:** 2023-12-31
- **Target enrollment:** 416 (ESTIMATED)
- **Last updated:** 2021-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040906, "A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05040906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*